Key result
Elevated arterial lysozyme is linked to a ~107% increase in long-term all-cause mortality.
Why the study?
Does elevated arterial lysozyme concentration predict all-cause mortality in patients undergoing coronary angiography?
Cohort (n=399)
Does elevated arterial lysozyme concentration predict all-cause mortality in patients undergoing coronary angiography?
Answers are grounded in this paper and cite their sources.
Elevated arterial lysozyme concentration is a strong, independent predictor of long-term all-cause mortality in patients undergoing coronary angiography.
Background Atherosclerotic cardiovascular disease (CVD) remains the leading cause of global mortality, necessitating robust biomarkers for improved risk stratification and early intervention. Plasma lysozyme has demonstrated excellent diagnostic accuracy for CAD. However, its prognostic significance in long-term mortality remains unexplored. This study investigates the association between baseline arterial lysozyme concentration and all-cause mortality in a well-characterised cohort, evaluating its potential as a predictive biomarker for adverse outcomes in CAD. Methods We performed a long-term follow-up of a previously established cohort of 399 patients who underwent coronary angiography. Arterial lysozyme concentrations were measured via enzyme-linked immunosorbent assay (ELISA), with clinical and demographic data recorded at baseline. The primary endpoint was all-cause mortality, determined through linkage with national death registries and hospital records. Survival analysis was conducted using Kaplan-Meier curves. Cox proportional hazards regression models were employed to assess the independent association of lysozyme with mortality, adjusting for key confounders including age, sex, comorbidities, and traditional cardiovascular risk factors. A data-driven threshold of 1.5 was identified as the optimal cut-off for defining high-risk individuals. Results Over a median follow-up of 16 years (IQR: 15–20), elevated arterial lysozyme concentration was significantly associated with increased mortality risk in both univariate (HR = 1.06, 95% CI: 1.03–1.08, p < 0.001) and multivariate analysis (HR = 1.10, 95% CI: 1.04–1.15, p < 0.001). Stratification using the 1.5 threshold demonstrated high sensitivity (86.9%) and specificity (87.3%) for CAD risk. Patients in the high lysozyme group had a significantly increased mortality hazard (univariate HR = 2.42, 95% CI: 1.63–3.60, p < 0.001; multivariate HR = 2.07, 95% CI: 1.23–3.50, p = 0.006). Kaplan-Meier survival analysis (Figure 1) further confirmed a markedly reduced survival probability in the high lysozyme group (p < 0.0001), reinforcing its prognostic significance. Conclusion Elevated arterial lysozyme concentration is a powerful and independent predictor of long-term mortality in patients undergoing coronary angiography. The identified threshold of 1.5 effectively stratifies high-risk individuals, demonstrating strong predictive value beyond traditional cardiovascular risk factors. These findings position arterial lysozyme as a promising biomarker for risk assessment in atherosclerosis, warranting further investigation into its mechanistic role and potential integration into clinical decision-making to enhance early intervention and patient outcomes.
No takes yet. Share an insight, caveat, or question.
Fathieh et al. (2025) conducted a cohort in Coronary artery disease (n=399). Elevated arterial lysozyme concentration (≥1.5) vs. Low arterial lysozyme concentration (<1.5) was evaluated on All-cause mortality (HR 2.07, 95% CI 1.23-3.50, p=0.006). Elevated arterial lysozyme concentration was independently associated with increased long-term all-cause mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: